Navigation Links
Gilead's AIDS Drug Awaits Patent in India

American bio-pharmaceutical major Gilead, which has entered into generic licensing deals with 10 Indian pharma firms to distribute its HIV drug Viread, is hoping to get a patent in India soon.

"We have made considerable progress in implementing our access programme and licensed Indian pharmas to manufacture Viread which originally announced a pricing of $1 a day for the pill," Gregg Alton, senior vice president and general counsel, Gilead Sciences, told IANS.

"After much discussion, Gilead now believes that a larger number of manufacturers will intensify competition and drive down prices even further," said Alton whose team was in Delhi last week.

Now, Gilead's application for a patent is pending before the Indian Patent office as it believes that it has a right to protect its intellectual property.

Indian pharma major Cipla has filed a pre-grant opposition against the patent application for Viread before the patents office.

But Alton said: "We believe that protecting the intellectual property of companies who engage in drug research and development is a critical part of the treatment access equation. Intellectual property protection, when used responsibly, encourages research and discovery of newer and more effective molecules.

"Gilead respects Cipla's right to oppose the issuance of a patent for Viread or any drug. But more importantly, we reaffirm our desire to work with Cipla whether or not a patent is issued," said Alton.

Gilead has signed generic licensing deals with 10 Indian pharma majors to distribute Viread in India and 94 other resource-limited countries.

More than 5.1 million people are believed to be infected with HIV in India - the second highest incidence of the disease after South Africa.

According to Alton, Viread (tenofovir disoproxil fumarate) is on its way to becoming the frontrunner drug across Europe for HIV/AIDS due to its low toxicity and resistance levels observed in patients.

The tablet-a-day dosage of the drug also helps in better regimen and compliance among the HIV/AIDS patients taking it.

Alton also pointed out that he expects generic versions of Gilead's anti-retrovirals to be available from several of its partners within the next few months.

When asked whether the drug would become unaffordable if Gilead was granted a patent for Viread in India, Alton assuaged fears voiced by critics and NGOs.

"The company plans to use this patent responsibly and has made its intention clear in the act of issuing non-exclusive voluntary licenses to Indian companies," he said.

"We have also planned a direct contact programme with NGOs and this open mode of communication will enable NGOs and Gilead to work on a common platform and fight the epidemic of AIDS together."

Currently, Gilead has signed agreements with Alkem Laboratories Ltd., Aurobindo Pharma Ltd., Emcure Pharmaceuticals, FDC Ltd., Hetero Drugs, Matrix Laboratories Ltd., Medchem International, Ranbaxy Laboratories Ltd., Shasun Chemicals & Drugs Ltd and Strides Arcolab Ltd.


'"/>




Related medicine news :

1. Vaccine For Cervical Cancer Awaits Approval
2. India Awaits Test Results To Confirm The Bird Flu Virus In Humans
3. Three-year-old AIDS Patient Awaits Death
4. Pfizer Awaits FDA Approval for New AIDS Drug, Maraviroc
5. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
6. HIV Patients Opposes Patenting Of AIDS Drug
7. Provigil Patent Extension Accorded To Cephalon
8. AIDS Sufferers Protest against Proposed Patent for Tenofovir
9. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
10. Venus Remedies Files 5th International Patent Application
11. US Court Rules Against Lupin in Ramipril Patent Case
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... ... 17, 2017 , ... SC&H Group, a leading audit, tax, and consulting firm, ... IT Advisory Services practice . Rossi is the third technology consulting leader to join ... guidance grows, and the practice continues to expand.     , Bringing more than 25 years ...
(Date:1/17/2017)... ... 2017 , ... Seceon , the only threat detection ... announced a strategic partnership with TechLab Security, a leading Enterprise Systems ... Security has become a strategic partner and a value added reseller of Seceon’s ...
(Date:1/17/2017)... TX (PRWEB) , ... January 17, 2017 , ... ... Texas families from two offices in Tyler, has announced the latest beneficiary of ... Ribbon Wish Network, a nonprofit organization dedicated to fulfilling the dreams of terminally ...
(Date:1/17/2017)... ... 2017 , ... Many people make New Year’s resolutions or renew their commitment to better health ... easier for people who want to kick off 2017 with better smiles. Dr. Mondavi is ... These special offers include: , , A new patient package for ...
(Date:1/17/2017)... Litlle Falls, NJ (PRWEB) , ... January 17, ... ... Museum and Learning Center and the Montclair State University’s Athletic Training Education program ... Montclair State University’s Athletic Training Education Program, which is consists of both ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... Research and Markets has announced the addition of the "Non-Invasive ... Growth Potential, Competitive Strategies and Forecasts: 2017 - 2021" report ... ... 11 major NIPT test by the year end of 2021. ... market and contains thoughtful insights, facts, historical data, and statistically supported ...
(Date:1/16/2017)... -- Infusion pumps and accessories are class of ... a controlled, precise and automated manner. These devices ... care, pain management and other applications, where continuous ... and pain free. These infusion systems help in ... life threatening circumstances or even sometimes to death ...
(Date:1/16/2017)... , Jan. 16, 2017   The Harrington ... Cleveland, Ohio , has announced the ... support breakthrough discoveries of physician-scientists whose research shows ... The Harrington Discovery Institute – part of ... an unmet need in academic medicine: to advance ...
Breaking Medicine Technology: